{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Bone mineral density was assessed using dual energy X ray absorptiometry scans at screening and approximately 1 year after treatment initiation. Participants with evaluable scans within the protocol specified assessment window were included in the analysis.","groups":[{"description":"Denosumab: 120mg of Denosumab will be administered subcutaneously once every 4 weeks","id":"OG000","title":"Denosumab"}],"paramType":"NUMBER","populationDescription":"The analysis includes participants with evaluable bone mineral density assessments at the 1 year time point.","reportingStatus":"POSTED","timeFrame":"1 year","title":"Proportion of Participants With Change in Bone Mineral Density From Screening to 1 Year","type":"SECONDARY","unitOfMeasure":"participants"}